Literature DB >> 10892762

Immune reactivity to glutamic acid decarboxylase 65 in stiffman syndrome and type 1 diabetes mellitus.

T Lohmann1, M Hawa, R D Leslie, R Lane, J Picard, M Londei.   

Abstract

BACKGROUND: The immune response to an isoform of glutamic acid decarboxylase (GAD), GAD65, is associated with two clinically distinct diseases, stiff-man syndrome (SMS) and type 1 (insulin-dependent) diabetes mellitus. We sought to identify differences in the cellular and humoral immune responses to GAD in these two diseases.
METHODS: We compared T-cell responses in 14 SMS patients with axial disease and 17 patients with type 1 diabetes.
FINDINGS: Peripheral blood T cells of eight SMS patients recognised different immunodominant epitopes of GAD65 compared with T cells from 17 patients with type 1 diabetes. GAD regions 81-171 and 313-403 induced a dominant T-cell response in six of eight patients with SMS but in only one of 17 patients with type 1 diabetes (p=0.001). No SMS patients responded dominantly to GAD fragments 161-243 and 473-555 compared with ten patients with type 1 diabetes (p=0.008). GAD antibodies were detected in 11 of 14 SMS patients (seven with diabetes) and 11 of 17 patients with type 1 diabetes; IgG1 was dominant in both groups. SMS patients, however, were more likely than patients with diabetes to have isotypes other than IgG1 (p=0.03), in particular, IgG4 or IgE isotypes, which were not detected in patients with type 1 diabetes (p=0.012).
INTERPRETATION: Our findings indicate differences between patients with SMS and type 1 diabetes in cellular (epitope recognition) and humoral (isotype pattern) responses to GAD65. Thus the same autoantigen can elicit distinct immune responses in patients with SMS, even when associated with diabetes, compared with patients with type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10892762     DOI: 10.1016/S0140-6736(00)02431-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  27 in total

Review 1.  Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?

Authors:  M Peakman; C M Dayan
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

2.  Cerebellar degeneration and polyglandular autoimmune syndrome with anti-glutamic acid decarboxylase antibodies.

Authors:  S Rüegg; M Stahl; M Bühlmann; A Dupont; P A Lyrer; R L Humbel; A J Steck
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

Review 3.  GAD antigen and its significance in type I diabetes.

Authors:  M I Hawa; R D G Leslie
Journal:  J Endocrinol Invest       Date:  2002 Jul-Aug       Impact factor: 4.256

4.  GAD65 antibody isotypes and epitope recognition during the prediabetic process in siblings of children with type I diabetes.

Authors:  S Hoppu; M S Ronkainen; P Kulmala; H K Akerblom; M Knip
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

5.  Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff-person syndrome but without type 1 diabetes.

Authors:  Arno Hänninen; Merja Soilu-Hänninen; Christiane S Hampe; Angie Deptula; Kelly Geubtner; Jorma Ilonen; Mikael Knip; Helena Reijonen
Journal:  Diabetes Metab Res Rev       Date:  2010-05       Impact factor: 4.876

Review 6.  CNS immune privilege: hiding in plain sight.

Authors:  Monica J Carson; Jonathan M Doose; Benoit Melchior; Christoph D Schmid; Corinne C Ploix
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

7.  Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies.

Authors:  S Vulliemoz; G Vanini; A Truffert; C Chizzolini; M Seeck
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02       Impact factor: 10.154

8.  Determination of glutamic acid decarboxylase antibodies (GADA) IgG subclasses - comparison of three immunoprecipitation assays (IPAs).

Authors:  M Hillman; C Törn; M Landin-Olsson
Journal:  Clin Exp Immunol       Date:  2007-07-30       Impact factor: 4.330

Review 9.  Clinical potential of antigen-specific therapies in type 1 diabetes.

Authors:  Ken T Coppieters; Birgit Sehested Hansen; Matthias G von Herrath
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 10.  Trials in type 1 diabetes: Antigen-specific therapies.

Authors:  Ken T Coppieters; Leonard C Harrison; Matthias G von Herrath
Journal:  Clin Immunol       Date:  2013-02-15       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.